Inovio Pharmaceuticals
89 hedge funds and large institutions have $56.4M invested in Inovio Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 19 increasing their positions, 31 reducing their positions, and 50 closing their positions.
116% more capital invested
Capital invested by funds: $26.2M → $56.4M (+$30.2M)
15.85% more ownership
Funds ownership: 1.55% → 17.4% (+16%)
3% more call options, than puts
Call options by funds: $5.24M | Put options by funds: $5.08M
21% less funds holding
Funds holding: 113 → 89 (-24)
39% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 31
46% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.01M |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$922K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$671K |
| 4 |
HF
HRT Financial
New York
|
+$561K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$449K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$2.04M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.38M |
| 3 |
Renaissance Technologies
New York
|
-$1.36M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$685K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$456K |
INO Hedge Fund Activity: Q1 2024 in Review
89 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2024, worth a combined $56.4M — up 116% from $26.2M a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of INO and 27 opened new positions — a net loss of 23 holders — while 31 trimmed existing stakes and 19 added.
The largest buyer was Millennium Management, adding an estimated $2.01M. The largest seller was GSA Capital Partners, cutting an estimated $2.04M.
- 89 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2024, down from 113 in Q4 2023.
- Funds reported $56.4M of Inovio Pharmaceuticals stock for Q1 2024, up 116% quarter-over-quarter.
- 27 funds opened new Inovio Pharmaceuticals positions in Q1 2024 and 50 closed out, a net change of -23 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2024 was Millennium Management, an estimated $2.01M added.
- The largest Inovio Pharmaceuticals seller in Q1 2024 was GSA Capital Partners, an estimated $2.04M sold.
Based on aggregated 13F filings for Q1 2024.